Biomarkers
Conditions
Keywords
Sugar sweetened beverage, biomarker
Brief summary
This study is a secondary analysis of data collected in the Nurses' Health Study (NHS) that will evaluat the association between intake of sugar sweetened beverages (SSB), juice and artificially sweetened beverages in relation to biomarkers of hepatic function, lipid metabolism, inflammation and glycemic control.
Detailed description
The investigators will analyze cross-sectional data from 8,492 participants in the Nurses' Health Study who were free of diabetes and cardiovascular disease to evaluate the association between intake of sugar sweetened beverages (SSB), juice and artificially sweetened beverages (ASB) and biomarkers of hepatic function, lipid metabolism, inflammation and glycemic control. Biomarkers were measured from blood samples that were collected in 2 cycles, approximately 10 years apart. Specifically, multivariate linear regression will be used to assess the associations of SSB, ASB, and fruit juice intake with concentrations of fetuin-A, alanine transaminase, gamma-glutamyl transferase, triglycerides, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), total cholesterol, C-reactive protein (CRP), intracellular adhesion molecule 1 (ICAM-1), vascular cell adhesion protein 1 (VCAM-1), adiponectin, insulin, and hemoglobin A1c as well as total cholesterol/HDL-C ratio.
Interventions
OTHERSugar sweetened beverage (SSB)
This is an observational study examining sugar sweetened beverage intake in relation to biomarkers in the NHS.
Sponsors
Harvard School of Public Health (HSPH)
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
30 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
For the current study, we included participants who provided a blood sample and were previously selected as controls for nested case-control analyses of type 2 diabetes, coronary heart disease, stroke, colon cancer, colon polyps, pancreatic cancer, and breast cancer in the Nurse's Health Study.
Exclusion criteria
Participants with self-reported prevalent diabetes or cardiovascular disease (CVD) at blood draw were excluded. After exclusions, a total of 8,492 individuals (6,961 from cycle 1 and 1,531 from cycle 2) with valid beverage intake data were included in the current analysis.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Alanine transaminase | Blood collection cycle 1 (1989-1990) | Biomarkers of liver function |
| Gamma-glutamyl transferase | Blood collection cycle 1 (1989-1990) | Biomarkers of liver function |
| Fetuin-A | Blood collection cycle 1 (1989-1990) | Biomarkers of liver function |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Total cholesterol | Blood collection cycle 1 (1989-1990) | Biomarkers of lipid metabolism |
| Total cholesterol/HDL-C ratio | Blood collection cycle 1 (1989-1990) | Biomarkers of lipid metabolism |
| C-reactive protein (CRP) | Blood collection cycle 1 (1989-1990) | Biomarkers of inflammation |
| Triglycerides | Blood collection cycle 1 (1989-1990) | Biomarkers of lipid metabolism |
| Vascular cell adhesion protein 1 (VCAM-1) | Blood collection cycle 1 (1989-1990) | Biomarkers of inflammation |
| Insulin | Blood collection cycle 1 (1989-1990) | Biomarkers of glucose metabolism |
| Hemoglobin A1c | Blood collection cycle 1 (1989-1990) | Biomarkers of glucose metabolism |
| Intracellular adhesion molecule 1 (ICAM-1) | Blood collection cycle 1 (1989-1990) | Biomarkers of inflammation |
| High-density lipoprotein cholesterol (HDL-C) | Blood collection cycle 1 (1989-1990) | Biomarkers of lipid metabolism |
| Low-density lipoprotein cholesterol (LDL-C) | Blood collection cycle 1 (1989-1990) | Biomarkers of lipid metabolism |
Countries
United States
Outcome results
None listed